Drug Profile
Research programme: antithrombotics therapeutics - Aplagon/Cadila Pharmaceuticals
Alternative Names: APACLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Aplagon
- Class Anticoagulants; Antiplatelets; Antithrombotics
- Mechanism of Action Heparin antagonists; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Thrombosis(Prevention) in Finland
- 19 Sep 2017 Aplagon in collaboration with Cadila pharmaceuticals plans a phase I/II and phase II/III trials for Thrombosis (Prevention) in India in 2019
- 19 Sep 2017 Preclinical trials in Thrombosis (Prevention) in Finland (unspecified route)